Trials / Completed
CompletedNCT05127460
CARDIOLOGIST Trial: Artificial Intelligence Enabled Electrocardiogram for Atrial Fibrillation Detection
Computer-assisted Atrial Fibrillation Risk Detection In Oral-anticoagulant Use, Lowering Stroke Risk, and Optimizing Guidance With an Intelligent Screening Tool (CARDIOLOGIST): a Pragmatic Randomized Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 25,732 (actual)
- Sponsor
- National Defense Medical Center, Taiwan · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of Atrial Fibrillation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | AI-enabled ECG-based Screening Tool | Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding. |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2022-10-31
- Completion
- 2023-01-31
- First posted
- 2021-11-19
- Last updated
- 2023-03-28
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT05127460. Inclusion in this directory is not an endorsement.